Merck (NYSE:MRK), known as MSD outside the United States and
Canada, today announced the launch of ILÚM Health Solutions, which
provides enterprise-wide disease management tools and services to
enable improved outcomes for patients with infectious diseases,
such as sepsis and pneumonia, while supporting antimicrobial
stewardship initiatives. ILÚM operates independently from Merck’s
pharmaceutical and vaccine products businesses as part of Merck’s
Healthcare Services & Solutions (HSS) group.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170216005351/en/
“We are pleased to offer ILÚM in the United States as a way to
strategically partner with health systems to fight infectious
diseases and combat the threat of antimicrobial resistance,” said
Guy Eiferman, managing director, HSS. “It is an important step for
our Healthcare Services and Solutions business, and complements
Merck’s company-wide efforts to develop and deliver innovative
approaches to address some of today’s most pressing health
issues.”
ILÚM Insight™ – ID leverages data within existing hospital IT
systems to promote optimal decision making and appropriate use of
antimicrobials through its clinical decision support (CDS) system
and Command Center (an intuitive data dashboard). These solutions
enable case monitoring and prioritization—on an individual and
aggregate level based on disease state—and promote early
recognition of infectious diseases, appropriate interventions, and
adherence to evidence-based clinical pathways. They also provide
automated outcomes reporting that is configured to
hospital-specific initiatives to track quality program
performance.
In 2015, ILÚM initiated a collaboration with East Jefferson
General Hospital (EJGH), a 424-bed general medical and surgical
hospital in Metairie, La., to pilot ILÚM’s CDS system with an
initial focus on improving the impact of the hospital’s quality
program for sepsis care improvement. Sepsis is a potentially
life-threatening complication of an infection, resulting in 750,000
deaths in the United States and more than $20 billion in aggregate
costs annually, with studies demonstrating that hospitals spend
approximately $34,000 caring for each patient with severe
sepsis.
“East Jefferson General Hospital has a strong commitment to the
early recognition and management of sepsis, which are critical to
survival,” said Raymond DeCorte, chief medical officer, EJGH. “We
are partnering with ILÚM as part of an ongoing, hospital-wide
initiative targeting sepsis quality improvement, which includes
multi-disciplinary departmental collaborations and sponsorship from
administration and medical leadership. This innovative solution has
helped us to identify patients with sepsis faster, care for them
better and reduce the use of critical hospital resources. We look
forward to continuing to work with ILÚM to fight infection and
support our antimicrobial stewardship initiatives.”
Preliminary results from the EJGH pilot were presented at the
Institute for Healthcare Improvement’s 28th Annual National Forum
on Quality Improvement in Health Care in December 2016. Data showed
that with ILÚM’s CDS system, clinicians at EJGH improved their
identification of patients with severe sepsis and achieved high
adherence rates to the hospital’s guideline-based sepsis care
pathway. Comparing data from twelve months prior (control group,
May 2014 to April 2015) to twelve months after (study group,
September 2015 to August 2016) the ILÚM CDS implementation, there
was significant improvement in clinical outcomes and reduction in
utilization of healthcare resources. Among patients with all sepsis
types, a reduction in hospital length-of-stay (7.11 to 6.81 days;
p=0.05) was observed. Among patients with severe sepsis,
significantly fewer patients developed hospital-onset shock in the
study group compared to the control group (19 percent vs. 35
percent; p=0.006).
“The ILÚM team is focused on helping hospitals improve quality
and optimize care by working with doctors, nurses, quality
managers, pharmacists and hospital leadership every step of the
way,” said Dr. Brandon Palermo, executive director and chief
medical officer, HSS. “We are pleased with the results achieved to
date at EJGH, and look forward to presenting additional results,
including mortality data, at future healthcare conferences.”
About ILÚM Health Solutions
ILÚM Health Solutions is part of Merck’s Healthcare Services
& Solutions (HSS) group, an independent business unit focused
on improving the value of care delivered to patients through
evidence-based services and solutions. ILÚM Health Solutions is
organized and managed independently from Merck’s pharmaceutical
products business. For more information about ILÚM Health
Solutions, visit www.ILÚMhealthsolutions.com.
About Merck
For over a century, Merck has been a global health care leader
working to help the world be well. Merck is known as MSD outside
the United States and Canada. Through our prescription medicines,
vaccines, biologic therapies, and animal health products, we work
with customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment to
increasing access to health care through far-reaching policies,
programs and partnerships. For more information, visit
www.merck.com and connect with us on Twitter, Facebook, YouTube and
LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2015
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170216005351/en/
Media:Patrick Witmer, 267-305-4910orInvestors:Amy Klug,
908-740-1898
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024